The association between genetic polymorphism and risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
| Project/Area Number |
22790515
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Hyogo University of Health Sciences |
|---|
Principal Investigator |
NONEN Shinpei 兵庫医療大学, 薬学部, 講師 (40467527)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 前立腺癌 / ホルモン療法 / 遺伝子多型 / アンドロゲン除去症候群 |
|---|
| Research Abstract |
The hormone ablation therapy is the standard therapy for prostate cancer ; however, there is a large individual difference in the duration of response to the therapy. In this study, we have investigated the association between genetic polymorphic variations in steroidogenesis-related genes and risk of progression to Castration-Resistant Prostate Cancer(CRPC) in Japanese patients after androgen deprivation therapy.
The different genotypes were analyzed according to case-control status of progression to CRPC at 43 months after diagnosis that is a median duration of hormonal therapy in this cohort.
In the androgen deprivation therapy, the genetic polymorphisms in CYP17A1 are associated with a risk of progression to CPRC with statistic significance. The genetic backgrounds for CYP17A1 genes could influence the progression of prostate cancer to CRPC after androgen deprivation therapy.
|
Report
(3 results)
Research Products
(5 results)
